Harmony Biosciences Holdings, Inc. (HRMY) stock
HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.11+0.10 (+0.30%)
Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –
Harmony Biosciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Harmony Biosciences's total debt was $153.96M at Jun 30, 2026. For fiscal 2025 it was $163.66M, down 8.7% from the year before. The highest annual figure on record is $194.25M in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $163.66M | -8.7% |
| FY2024 | Dec 31, 2024 | $179.27M | -7.4% |
| FY2023 | Dec 31, 2023 | $193.57M | +1.0% |
| FY2022 | Dec 31, 2022 | $191.65M | -0.2% |
| FY2021 | Dec 31, 2021 | $191.98M | -1.2% |
| FY2020 | Dec 31, 2020 | $194.25M | +98.3% |
| FY2019 | Dec 31, 2019 | $97.95M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $153.96M | -10.5% |
| Q1 FY2026 | Mar 31, 2026 | $158.81M | -9.6% |
| Q4 FY2025 | Dec 31, 2025 | $163.66M | -8.7% |
| Q3 FY2025 | Sep 30, 2025 | $168.51M | -7.8% |
| Q2 FY2025 | Jun 30, 2025 | $172.10M | -7.7% |
| Q1 FY2025 | Mar 31, 2025 | $175.68M | -7.5% |
| Q4 FY2024 | Dec 31, 2024 | $179.27M | -7.4% |
| Q3 FY2024 | Sep 30, 2024 | $182.85M | -7.2% |
| Q2 FY2024 | Jun 30, 2024 | $186.42M | -2.6% |
| Q1 FY2024 | Mar 31, 2024 | $190.00M | -0.8% |
| Q4 FY2023 | Dec 31, 2023 | $193.57M | +1.0% |
| Q3 FY2023 | Sep 30, 2023 | $197.13M | +2.8% |
| Q2 FY2023 | Jun 30, 2023 | $191.49M | -0.2% |
| Q1 FY2023 | Mar 31, 2023 | $191.56M | -0.2% |
| Q4 FY2022 | Dec 31, 2022 | $191.65M | -0.2% |
| Q3 FY2022 | Sep 30, 2022 | $191.73M | -0.2% |
| Q2 FY2022 | Jun 30, 2022 | $191.81M | -1.9% |
| Q1 FY2022 | Mar 31, 2022 | $191.90M | -1.5% |
| Q4 FY2021 | Dec 31, 2021 | $191.98M | -1.2% |
| Q3 FY2021 | Sep 30, 2021 | $192.07M | -0.4% |
| Q2 FY2021 | Jun 30, 2021 | $195.61M | +99.7% |
| Q1 FY2021 | Mar 31, 2021 | $194.91M | – |
| Q4 FY2020 | Dec 31, 2020 | $194.25M | – |
| Q3 FY2020 | Sep 30, 2020 | $192.86M | – |
| Q4 FY2019 | Dec 31, 2019 | $97.95M | – |
See a number that looks wrong?